Therapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity
- PMID: 39729407
- PMCID: PMC11676559
- DOI: 10.1371/journal.pcbi.1012693
Therapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity
Abstract
Treatment for major depressive disorder (depression) often has partial efficacy and a large portion of patients are treatment resistant. Recent studies implicate reduced somatostatin (SST) interneuron inhibition in depression, and new pharmacology boosting this inhibition via positive allosteric modulators of α5-GABAA receptors (α5-PAM) offers a promising effective treatment. However, testing the effect of α5-PAM on human brain activity is limited, meriting the use of detailed simulations. We utilized our previous detailed computational models of human depression microcircuits with reduced SST interneuron inhibition and α5-PAM effects, to simulate EEG of individual microcircuits across depression severity and α5-PAM doses. We developed machine learning models that predicted optimal dose from EEG with high accuracy and recovered microcircuit activity and EEG. This study provides dose prediction models for α5-PAM administration based on EEG biomarkers of depression severity. Given limitations in doing the above in the living human brain, the results and tools we developed will facilitate translation of α5-PAM treatment to clinical use.
Copyright: © 2024 Guet-McCreight et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: ES and TP are listed inventors on patents covering syntheses and use of α5-PAM compounds. EH, ES, and TP are listed inventors and AGM and FM are listed as collaborators on a patent covering in-silico EEG biomarkers for dosage determination and monitoring α5-PAM treatment efficacy. ES is Founder and CSO, and TP is Director of Preclinical Research and Development of Damona Pharmaceuticals, a biopharma dedicated to bringing α5-PAM compounds to the clinic.
Figures





Similar articles
-
In-silico testing of new pharmacology for restoring inhibition and human cortical function in depression.Commun Biol. 2024 Feb 23;7(1):225. doi: 10.1038/s42003-024-05907-1. Commun Biol. 2024. PMID: 38396202 Free PMC article.
-
Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation.Int J Neuropsychopharmacol. 2021 Jul 14;24(6):505-518. doi: 10.1093/ijnp/pyab002. Int J Neuropsychopharmacol. 2021. PMID: 33438026 Free PMC article.
-
Electroencephalography Biomarkers of α5-GABA Positive Allosteric Modulators in Rodents.Biol Psychiatry Glob Open Sci. 2024 Dec 19;5(2):100435. doi: 10.1016/j.bpsgos.2024.100435. eCollection 2025 Mar. Biol Psychiatry Glob Open Sci. 2024. PMID: 39990628 Free PMC article.
-
Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives.Biol Psychiatry. 2017 Oct 15;82(8):549-559. doi: 10.1016/j.biopsych.2017.05.024. Epub 2017 Jun 8. Biol Psychiatry. 2017. PMID: 28697889 Free PMC article. Review.
-
Ketamine: Leading us into the future for development of antidepressants.Behav Brain Res. 2020 Apr 6;383:112532. doi: 10.1016/j.bbr.2020.112532. Epub 2020 Feb 2. Behav Brain Res. 2020. PMID: 32023492 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous